Teva Pharmaceutical Industries (NYSE:TEVA) Given New $13.00 Price Target at SunTrust Banks

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price increased by SunTrust Banks from $9.00 to $13.00 in a report published on Thursday, BenzingaRatingsTable reports. SunTrust Banks currently has a hold rating on the stock.

A number of other brokerages have also recently weighed in on TEVA. Cfra lifted their price target on Teva Pharmaceutical Industries from $11.00 to $13.00 and gave the stock a hold rating in a research note on Wednesday. Wells Fargo & Co lifted their price target on Teva Pharmaceutical Industries from $8.00 to $10.00 and gave the stock an equal weight rating in a research note on Wednesday, January 22nd. Gabelli raised Teva Pharmaceutical Industries from a hold rating to a buy rating in a research note on Wednesday, October 16th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an underweight rating to a neutral rating and set a $8.00 price target on the stock in a research note on Tuesday, November 12th. Finally, Bank of America raised Teva Pharmaceutical Industries from an underperform rating to a buy rating in a research note on Friday, January 3rd. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $11.71.

TEVA traded down $0.35 during trading on Thursday, reaching $12.22. The company had a trading volume of 32,752,861 shares, compared to its average volume of 20,229,391. The firm’s 50-day simple moving average is $10.41 and its 200 day simple moving average is $8.76. The company has a market cap of $13.49 billion, a price-to-earnings ratio of -3.16, a PEG ratio of 1.24 and a beta of 1.84. Teva Pharmaceutical Industries has a 12-month low of $6.07 and a 12-month high of $18.08. The company has a debt-to-equity ratio of 1.62, a quick ratio of 0.56 and a current ratio of 0.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.61 by $0.01. The firm had revenue of $4.47 billion for the quarter, compared to analysts’ expectations of $4.35 billion. Teva Pharmaceutical Industries had a positive return on equity of 15.41% and a negative net margin of 22.88%. Teva Pharmaceutical Industries’s revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the business posted $0.53 EPS. On average, sell-side analysts expect that Teva Pharmaceutical Industries will post 2.27 EPS for the current year.

In other news, VP David Matthew Stark sold 12,538 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $12.24, for a total transaction of $153,465.12. Following the completion of the sale, the vice president now directly owns 15,512 shares in the company, valued at approximately $189,866.88. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Brendan P. O’grady sold 4,799 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $12.27, for a total value of $58,883.73. Following the sale, the executive vice president now owns 18,255 shares of the company’s stock, valued at $223,988.85. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,647 shares of company stock worth $257,561. Company insiders own 0.49% of the company’s stock.

Several institutional investors have recently made changes to their positions in TEVA. Vanguard Group Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 6.7% during the 2nd quarter. Vanguard Group Inc. now owns 2,020,570 shares of the company’s stock valued at $18,649,000 after buying an additional 126,139 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 115.6% during the 2nd quarter. Invesco Ltd. now owns 118,576 shares of the company’s stock valued at $1,094,000 after buying an additional 63,585 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 50.9% during the 3rd quarter. Pacer Advisors Inc. now owns 5,219 shares of the company’s stock valued at $36,000 after buying an additional 1,760 shares during the last quarter. Commerzbank Aktiengesellschaft FI lifted its holdings in shares of Teva Pharmaceutical Industries by 49.4% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 8,682,389 shares of the company’s stock valued at $59,735,000 after buying an additional 2,869,139 shares during the last quarter. Finally, G&S Capital LLC lifted its holdings in Teva Pharmaceutical Industries by 49.9% in the 3rd quarter. G&S Capital LLC now owns 6,012 shares of the company’s stock worth $41,000 after purchasing an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 53.73% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Closed-End Mutual Funds

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.